Possible involvement of IGF-1 receptor and IGF-binding protein in insulin-induced enhancement of noradrenaline response in diabetic rat aorta

British Journal of Pharmacology

Volumn 140, Issue 2, 2003, Pages 285-294

  Kobayashi, Tsuneo ^a   Kaneda, Akihito ^a   Kamata, Katsuo ^a  

^a HOSHI UNIVERSITY   (Japan)

Author keywords

Contraction; Diabetes; IGF 1 receptor; IGFBP; Insulin

Indexed keywords

ANGIOTENSIN; INSULIN; MESSENGER RNA; NORADRENALIN; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ANIMAL MODEL; ANIMAL TISSUE; AORTA DISEASE; ARTICLE; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR SYSTEM; CONTROLLED STUDY; DIABETIC ANGIOPATHY; DOWN REGULATION; DRUG EFFECT; HYPERINSULINEMIA; INSULIN DEFICIENCY; MALE; NONHUMAN; ORGAN CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR UPREGULATION; STREPTOZOCIN DIABETES;

ANGIOTENSIN II; ANIMALS; AORTA; BLOOD GLUCOSE; BLOOD PRESSURE; CHOLESTEROL; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; INSULIN; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 4; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 5; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; MALE; NOREPINEPHRINE; ORGAN CULTURE TECHNIQUES; POTASSIUM; RATS; RATS, WISTAR; RECEPTOR, IGF TYPE 1; RNA, MESSENGER; VASOCONSTRICTION;

EID: 0141923069     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705438     Document Type: Article

References (44)

1. ABE, H., YAMADA, N., KAMATA, K., KUWAKI, T., SHIMADA, M., OSUGA, J., SHIONOIRI, F., YAHAGI, N., KADOWAKI, T., TAMEMOTO, H., ISHIBASHI, S., YAZAKI, Y. & MAKUUCHI, M. (1998). Hypertension, hypertriglyceridemia, and impaired endothelium-dependent vascular relaxation in mice lacking insulin receptor substrate-1. J. Clin. Invest., 101, 1784-1788.
2. ANWAR, A., ZAHID, A.A., PHILLIPS, L. & DELAFONTAINE, P. (2000). Insulin-like growth factor binding protein-4 expression is decreased by angiotensin II and thrombin in rat aortic vascular smooth muscle cells. Arterioscler. Throtnb. Vasc. Biol., 20, 370-376.
3. BAYES-GENIS, A., CONOVER, C.A. & SCHWARTZ, R.S. (2000). The insulin-like growth factor axis: a review of atherosclerosis and restenosis. Circ. Res., 86, 125-130.
4. BLAKESLEY, V.A., SCRIMGEOUR, A., ESPOSITO, D. & LE ROITH, D. (1996). Signaling via the insulin-like growth factor-I receptor: does it differ from insulin receptor signaling? Cytokine Growth Factor Rev., 7, 153-159.
5. BORNFELDT, K.E., ARNQVIST, H.J. & CAPRON, L. (1992). In vivo proliferation of vascular smooth muscle in relation to diabetes mellitus, insulin-like growth factor I and insulin. Diabetologia, 35, 104-108.
6. COHEN, R.A. (1995). The role of nitric oxide and other endothelium-derived vasoactive substances in vascular disease. Prog. Cardiovasc. Dis., 38, 105-128.
7. DAHLFORS, G. & ARNQVIST, H.J. (2000). Vascular endothelial growth factor and transforming growth factor-beta1 regulate the expression of insulin-like growth factor-binding protein-3, -4, and -5 in large vessel endothelial cells. Endocrinology, 141, 2062-2067.
8. DE VRIES, C., ESCOBEDO, J.A., UENO, H., HOUCK, K., FERRARA, N. & WILLIAMS, L.T. (1992). The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science, 255, 989-991.
9. DUAN, C., BAUCHAT, J.R. & HSIEH, T. (2000). Phosphatidylinositol 3-kinase is required for insulin-like growth factor-I-induced vascular smooth muscle cell proliferation and migration. Circ. Res., 86, 15-23.
10. DUAN, C. & CLEMMONS, D.R. (1998). Differential expression and biological effects of insulin-like growth factor-binding protein-4 and -5 in vascular smooth muscle cells. J. Biol. Chem., 273, 16836-16842.
11. DUBEY, R.K., ZHANG, H.Y., REDDY, S.R., BOEGEHOLD, M.A. & KOTCHEN, T.A. (1993). Pioglitazone attenuated hypertension and inhibits growth of renal arteriolar smooth muscle cells. Am. J. Physiol., 265, R726-R732.
12. ECKEL, R.H., WASSEF, M., CHAIT, A., SOBEL, B., BARRETT, E., KING, G., LOPES-VIRELLA, M., REUSCH, J., RUDERMAN, N., STEINER, G. & VLASSARA, H. (2002). Prevention Conference VI: diabetes and cardiovascular disease: Writing Group II: pathogenesis of atherosclerosis in diabetes. Circulation, 105, 138-143.
13. FEENER, E.P. & KING, G.L. (1997). Vascular dysfunction in diabetes mellitus. Lancet, 350, 9-13.
14. GANS, R.O., BILO, H.J., VON MAARSCHALKERWEERD, W.W., HEINE, R.J., NAUTA, J.J. & DONKER, A.J. (1991). Exogenous insulin augments in healthy volunteers the cardiovascular reactivity to noradrenaline but not to angiotensin II. J. Clin. Invest., 88, 512-518.
15. GERHARDINGER, C., MCCLURE, K.D., ROMEO, G., PODESTA, F. & LORENZI, M. (2001). IGF-I mRNA and signaling in the diabetic retina. Diabetes, 50, 175-183.
16. GRANT, M.B., WARGOVICH, T.J., ELLIS, E.A., CABALLERO, S., MANSOUR, M. & PEPINE, C.J. (1994). Localization of insulin-like growth factor I and inhibition of coronary smooth muscle cell growth by somatostatin analogues in human coronary smooth muscle cells. A potential treatment for restenosis? Circulation, 89, 1511-1517.
17. HALL, J.E., BRANDS, M.W., ZAPPE, D.H. & GALICIA, M.A. (1995). Insulin resistance, hyperinsulinaemia, and hypertension: causes, consequences, or merely correlations? Proc. Soc. Exp. Biol. Med., 208, 317-329.
18. 1-adrenergic receptor subtype expression in rat vascular smooth muscle cells. J. Clin. Invest., 98, 1826-1834.
19. IMAI, Y., BUSBY JR, W.H., SMITH, C.E., CLARKE, J.B., GARMONG, A.J., HORWITZ, G.D., REES, C. & CLEMMONS, D.R. (1997). Protease-resistant form of insulin-like growth factor-binding protein 5 is an inhibitor of insulin-like growth factor-I actions on porcine smooth muscle cells in culture. J. Clin. Invest., 100, 2596-2605.
20. JEHLE, P.M., JEHLE, D.R., MOHAN, S. & BOHM, B.O. (1998). Serum levels of insulin-like growth factor system components and relationship to bone metabolism in Type 1 and Type 2 diabetes mellitus patients. J. Endocrinol., 159, 297-306.
21. KAMYAR, A., PIROLA, C.J., WANG, H.M., SHARIFI, B., MOHAN, S., FORRESTER, J.S. & FAGIN, J.A. (1994). Expression and insulin-like growth factor-dependent proteolysis of insulin-like growth factor-binding protein-4 are regulated by cell confluence in vascular smooth muscle cells. Circ. Res., 74, 576-585.
22. KANIE, N. & KAMATA, K. (2002). Effects of chronic administration of the novel endothelin antagonist J-104132 on endothelial dysfunction in streptozotocin-induced diabetic rat. Br. J. Pharmacol., 135, 1935-1942.
23. KING, G.L., GOODMAN, D., BUZNEY, S., MOSES, A. & KAHN, C.R. (1985). Receptors and growth promoting effects of insulin and insulin-like growth factors on cells from bovine retinal capillaries and aorta. J. Clin. Invest., 75, 1028-1036.
24. KIRPICHNIKOV, D. & SOWERS, J.R. (2001). Diabetes mellitus and diabetes-associated vascular disease. Trends Endocrinol. Metab., 12, 225-230.
25. KOBAYASHI, T., & KAMATA, K. (1999). Effect of insulin treatment on smooth muscle contractility and endothelium-dependent relaxation in rat aortae from established STZ-induced diabetes. Br. J. Pharmacol., 127, 835-842.
26. KOBAYASHI, T. & KAMATA, K. (2002). Short-term insulin treatment and aortic expression of IGF-1 receptor and VEGF mRNA in diabetic rats. Am. J. Physiol. Heart Circ. Physiol., 283, H1761-H1768.
27. KOBAYASHI, T., MATSUMOTO, T. & KAMATA, K. (2000). Mechanisms underlying the chronic pravastatin treatment-induced improvement in the impaired endothelium-dependent aortic relaxation seen in streptozotocin-induced diabetic rats. Br. J. Pharmacol., 131, 231-238.
28. OH, Y., NAGALLA, S.R., YAMANAKA, Y., KIM, H.S., WILSON, E. & ROSENFELD, R.G. (1996). Synthesis and characterization of insulin-like growth factor-binding protein (IGFBP)-7. Recombinant human mac25 protein specifically binds IFG-I and -II. J. Biol. Chem., 271, 30322-30325.
29. PFEIFLE, B. & DITSCHUNEIT, H. (1983). Two separate receptors for insulin and insulin-like growth factors on arterial smooth muscle cells. Exp. Clin. Endocrrinol., 81, 280-286.
30. POLANCO, J.I., BERCIANO, M.T., LAFARGA, M., LEON, J., POCOVI, M. & RODRIGUEZ-REY, J.C. (1995). Expression of insulin-like growth factor receptor mRNA in rabbit atherosclerotic lesions. Biochem. Biophys. Res. Commun., 209, 182-190.
31. PRICE, G.J., BERKA, J.L., WERTHER, G.A. & BACH, L.A. (1997). Cell-specific regulation of mRNAs for IGF-I and IGF-binding proteins-4 and -5 in streptozotocin-diabetic rat kidney. J. Mol. Endocrinol., 18, 5-14.
32. RAISANEN-SOKOLOWSKI, A., TILLY KIESI, M., USTINOV, J., MENNANDER, A., PAAVONEN, T., TIKKANEN, M.J. & HAYRY, P. (1994). Hyperlipidemia accelerates allograft arteriosclerosis (chronic rejection) in the rat. Arterioscler. Thromb., 14, 2032-2042.
33. RAZ, I., RUBINGER, D., POPOVTZER, M., GRONBAEK, H., WEISS, O. & FLYVBJERG, A. (1998). Octreotide prevents the early increase in renal insulin-like growth factor binding protein 1 in streptozotocin diabetic rats. Diabetes, 47, 924-930.
34. REAVEN, G.M. (1995). Pathophysiology of insulin resistance in human disease. Physiol. Rev., 75, 473-486.
35. SMITH, L.E., SHEN, W., PERRUZZI, C., SOKER, S., KINOSE, F., XU, X., ROBINSON, G., DRIVER, S., BISCHOFF, J., ZHANG, B., SCHAEFFER, J.M. & SENGER, D.R. (1999). Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat. Med., 5, 1390-1395.
36. STANDLY, P., BAKIR, M. & SOWER, J.R. (1993). Vascular insulin abnormalities, hypertension, and accelerated atherosclerosis. Am. J. Kidney, 21, 39-46.
37. TACK, C.J., SMITS, P., WILLEMSEN, J.J., LENDERS, J.W., THIEN, T. & LUTTERMAN, J.A. (1996). Effects of insulin on vascular tone and sympathetic nervous system in NIDDM. Diabetes, 45, 15-22.
38. TOWNSEND, R.R., YAMAMOTO, R., NICKOLS, M., DIPETTE, D.J. & NICKOLS, G.A. (1992). Insulin enhances pressor responses to norepinephrine in rat mesenteric vasculature. Hypertension, 19, II105-II110.
39. WALKER, A.B., CHATTINGTON, P.D., BUCKINGHAM, R.E. & WILLIAMS, G. (1999). The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in zucker fatty rats. Diabetes, 48, 1448-1453.
40. WANG, J., NIU, W., WITTE, D.P., CHERNAUSEK, S.D., NIKIFOROV, Y.E., CLEMENS, T.L., SHARIFI, B., STRAUCH, A.R. & FAGIN, J.A. (1998). Overexpression of insulin-like growth factor-binding protein-4 (IGFBP-4) in smooth muscle cells of transgenic mice through a smooth muscle alpha-actin-IGFBP-4 fusion gene induces smooth muscle hypoplasia. Endocrinology, 139, 2605-2614.
41. WARREN, R.S., YUAN, H., MATLI, M.R., FERRARA, N. & DONNER, D.B. (1996). Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma. J. Biol. Chem., 271, 29483-29488.
42. WU, H.Y., JENG, Y.Y., YUE, C.J., CHYU, K.Y., HSUEH, W.A. & CHAN, T.M. (1994). Endothelial-dependent vascular effects of insulin and insulin-like growth factor I in the perfused rat mesenteric artery and aortic ring. Diabetes, 43, 1027-1032.
43. ZENG, G. & QUON, M.J. (1996). Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J. Clin. Invest., 98, 894-898.
44. ZHAO, G., SUTLIFF, R.L., WEBER, C.S., WANG, J., LORENZ, J., PAUL, R.J. & FAGIN, J.A. (2001). Smooth muscle-targeted overexpression of insulin-like growth factor I results in enhanced vascular contractility. Endocrinology, 142, 623-632.